Amphastar Pharmaceuticals Inc has a consensus price target of $45.86, established from looking at the 12 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and JP Morgan on May 9, 2024, April 10, 2024, and March 5, 2024. With an average price target of $20 between Needham, Needham, and JP Morgan, there's an implied -52.62% downside for Amphastar Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Amphastar Pharma (NASDAQ: AMPH) was reported by Needham on May 9, 2024. The analyst firm set a price target for $0.00 expecting AMPH to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Amphastar Pharma (NASDAQ: AMPH) was provided by Needham, and Amphastar Pharma reiterated their hold rating.
The last upgrade for Amphastar Pharmaceuticals Inc happened on January 7, 2022 when Piper Sandler raised their price target to $28. Piper Sandler previously had a neutral for Amphastar Pharmaceuticals Inc.
There is no last downgrade for Amphastar Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amphastar Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amphastar Pharma was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
While ratings are subjective and will change, the latest Amphastar Pharma (AMPH) rating was a reiterated with a price target of $0.00 to $0.00. The current price Amphastar Pharma (AMPH) is trading at is $42.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.